Entre pacientes que recebem vacina de mRNA, sintomas clinicamente significativos são mais frequentes após a 2ª dose, após a 1ª dose em pacientes com infecção prévia por SARS-CoV-2 e naqueles que receberam a vacina da Moderna.

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers – JAMA Internal Medicine

Comentário no Twitter

New @JAMA_current paper says @moderna_Tx caused 2.3x the number of "significant" symptoms compared to @pfizer in a sample of 950 people.

Moderna also produced more antibodies. Raising the question of what a third dose, which produces still MORE, will do.https://t.co/drvhhsnpHo

— Alex Berenson (@AlexBerenson) August 16, 2021